Combined Factor VIII Replacement and Tolerance Therapy for Hemophilia A
A 型血友病联合因子 VIII 替代和耐受治疗
基本信息
- 批准号:8508305
- 负责人:
- 金额:$ 37.64万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-07-15 至 2016-06-30
- 项目状态:已结题
- 来源:
- 关键词:Antibody FormationAntigen PresentationAntigen TargetingBindingBiological MarkersBlocking AntibodiesBlood Coagulation FactorCell LineCellsChemicalsClinical ResearchClinical TrialsClinical Trials DesignCoagulation ProcessCollaborationsComplexDiseaseDoseDrug FormulationsEndogenous FactorsEngineeringEnzyme-Linked Immunosorbent AssayEpitopesEvaluationFactor VIIIFermentationFlow CytometryFutureGoalsHalf-LifeHealthHealth SciencesHemophilia AHemorrhageHumanImmune ToleranceImmune responseImmune systemImmunoglobulinsImmunologistImmunologyImmunosuppressive AgentsIn VitroIncidenceInfectionInflammationInfusion proceduresInterventionKnockout MiceLigandsLinkLiquid substanceMass Spectrum AnalysisMeasuresMediatingMethodsModelingMonitorMusNeoadjuvant TherapyOutcomePathway interactionsPatientsPeripheral Blood Mononuclear CellPharmaceutical PreparationsPhasePhenotypePositioning AttributePreventionProcessProductionProteinsProtocols documentationPublicationsRecombinantsRegulatory T-LymphocyteReplacement TherapyResearchRiskRunningSalineServicesSmall Business Innovation Research GrantSurface AntigensT cell responseT-LymphocyteTarget PopulationsTestingTherapeuticThrombosisUniversitiesWorkchemical conjugatecost effectivecytokinedrug developmentexperiencegel electrophoresishuman F8 proteinimmune functionimmunogenicityimmunoregulationin vivoinhibitor/antagonistinterestneutralizing antibodynovelphase 2 studyprogramsresponse
项目摘要
DESCRIPTION (provided by applicant): The goal of this new SBIR program is to produce a combined clotting Factor VIII replacement and immunomodulatory therapy that will provide FVIII-specific tolerance induction at therapeutic doses for Hemophilia A patients. Hemophiliacs with <1% functional FVIII are classified as severe and must receive regular doses of replacement factor. A major issue with successful FVIII replacement therapy for Hemophilia A is overcoming the neutralizing antibody response against FVIII that is seen in up to 30% of hemophiliacs and 50% of patients with severe disease. These "inhibitors" delay or inhibit clotting by interfering with FVIII binding to its ligands. A number of treatments for inhibitors exist but these approaches are either not fully successful or still experimental and present a large health risk for the patient. There is an urgent need for a safe, biologically rational and cost effective approach to induce long-term immune tolerance to FVIII. "Tregitopes" are immunoglobulin-derived natural regulatory T-cell (nTreg) epitopes that expand a subset of circulating nTregs, leading to suppression of inflammation and, when administered with a target antigen, adaptive tolerance. Since publication of this discovery in 2008, we have shown that presentation of Tregitopes at the surface of antigen presentation cells (APCs) to nTregs drives tolerogenic pathways in both APCs and nTregs, and induces target-antigen specific adaptive Tregs that interface with the same APC. Thus, as a natural immune system 'off switch,' Tregitopes have great potential as therapeutics to induce immunological tolerance to co-administered proteins. We therefore propose to couple Tregitopes to FVIII to produce a novel combined replacement and tolerance induction therapy. In this Phase I proof-of concept application, we propose to (i) demonstrate that FVIII-Tregitope modulates human T cell responses and establish correlates of tolerance induction that may be used in clinical trial design and (ii) demonstrate FVIII-Tregitope-mediated tolerance induction in an in vivo hemophilia model, which enables evaluation of Tregitope efficacy on the key outcome - elimination of inhibitors. In future Phase II studies, we will transition to recombinant production of FVIII-Tregitope, a process too complex and costly for proof-of-concept studies. ProBioGen, our Phase II collaborator, is a leading company with expertise in activities central to the manufacture of recombinant human FVIII, including cell line engineering, upstream fermentation, downstream purification, liquid pre-formulation of bulk drug substance and in-process analytics including titer determination and chromogenic determination of FVIII bioactivity. In addition, we have established a strong collaboration with a large Pharma that has experience in the regulatory and clinical trial aspects of FVIII drug development and anticipate that FVIII-Tregitope will move into clinical studies once we achieve the goals of the SBIR program.
描述(由申请人提供):这一新的SBIR计划的目标是产生一种凝血因子VIII替代和免疫调节疗法的组合,将在治疗剂量为血友病A患者提供FVIII特异性耐受诱导。有1%功能性FVIII的血友病患者被归类为严重血友病患者,必须定期服用替代因子。成功的FVIII替代疗法治疗血友病A的一个主要问题是克服针对FVIII的中和抗体反应,这种中和抗体反应见于多达30%的血友病患者和50%的严重疾病患者。这些“抑制物”通过干扰FVIII与其配体的结合来延迟或抑制凝血。目前存在一些针对抑制剂的治疗方法,但这些方法要么不完全成功,要么仍处于实验阶段,对患者的健康构成了巨大的风险。迫切需要一种安全的、生物上合理的和成本效益高的方法来诱导对FVIII的长期免疫耐受。“三重表位”是免疫球蛋白衍生的自然调节性T细胞(NTreg)表位,它可以扩展循环中nTregs的一个子集,从而抑制炎症,当与靶抗原一起使用时,还能产生适应性耐受。自2008年发表这一发现以来,我们已经证明,在抗原提呈细胞(APC)表面向nTregs递呈Tregitope可以驱动APC和nTregs中的耐受通路,并诱导与相同APC相互作用的靶抗原特异性适应性Tregs。因此,作为一种天然免疫系统的“开关”,Tregitope具有巨大的治疗潜力,可以诱导对联合给药蛋白质的免疫耐受。因此,我们建议将Tregitope与FVIII偶联,以产生一种新的联合替代和耐受诱导疗法。在这一阶段的概念验证应用中,我们建议(I)证明FVIII-Tregitope调节人类T细胞反应,并建立可用于临床试验设计的耐受诱导的相关性,以及(Ii)在体内血友病模型中证明FVIII-Tregitope介导的耐受诱导,这使得能够评估Tregitope在关键结果--消除抑制剂上的有效性。在未来的第二阶段研究中,我们将过渡到FVIII-Tregitope的重组生产,这一过程对于概念验证研究来说过于复杂和昂贵。ProBioGen是我们的第二阶段合作伙伴,是一家领先的公司,在生产重组人FVIII的核心活动方面拥有专业知识,包括细胞线工程、上游发酵、下游纯化、原料药的液体预配方和过程中分析,包括FVIII生物活性的滴度测定和显色测定。此外,我们还与一家在FVIII药物开发的监管和临床试验方面拥有经验的大型制药公司建立了强有力的合作关系,并预计一旦我们实现SBIR计划的目标,FVIII-Tregitope将进入临床研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Anne Searls DeGroot其他文献
Anne Searls DeGroot的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Anne Searls DeGroot', 18)}}的其他基金
ISPRI-HCP: CHO protein impurity immunogenicity risk prediction for improving biosimilar product development and assessing product interchangeability
ISPRI-HCP:CHO 蛋白杂质免疫原性风险预测,用于改进生物仿制药产品开发和评估产品互换性
- 批准号:
10620080 - 财政年份:2022
- 资助金额:
$ 37.64万 - 项目类别:
Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine
CD4 T细胞记忆增强rHA H7N9流感疫苗的结构引导设计
- 批准号:
9362529 - 财政年份:2017
- 资助金额:
$ 37.64万 - 项目类别:
Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine
CD4 T细胞记忆增强rHA H7N9流感疫苗的结构引导设计
- 批准号:
10216952 - 财政年份:2017
- 资助金额:
$ 37.64万 - 项目类别:
Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine
CD4 T细胞记忆增强rHA H7N9流感疫苗的结构引导设计
- 批准号:
9978692 - 财政年份:2017
- 资助金额:
$ 37.64万 - 项目类别:
Novel Antigen-Specific Immunomodulatory Tregitope-based Therapy to Address Autoimmune Pathogenesis in Graves' Disease
基于新型抗原特异性免疫调节 Tregitope 的疗法可解决格雷夫斯病的自身免疫发病机制
- 批准号:
9410057 - 财政年份:2017
- 资助金额:
$ 37.64万 - 项目类别:
Development of a Non-adjuvanted VLP Vaccine against Stealth H7N9 Influenza
针对隐形 H7N9 流感的无佐剂 VLP 疫苗的开发
- 批准号:
9304958 - 财政年份:2016
- 资助金额:
$ 37.64万 - 项目类别:
Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease
诱导对庞贝病酶替代疗法的耐受性
- 批准号:
8394488 - 财政年份:2012
- 资助金额:
$ 37.64万 - 项目类别:
Multi-intracellular Pathogen Epitope-based Vaccine
基于多细胞内病原体表位的疫苗
- 批准号:
8378738 - 财政年份:2012
- 资助金额:
$ 37.64万 - 项目类别:
Combined Factor VIII Replacement and Tolerance Therapy for Hemophilia A
A 型血友病联合因子 VIII 替代和耐受治疗
- 批准号:
8313747 - 财政年份:2012
- 资助金额:
$ 37.64万 - 项目类别:
相似海外基金
Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
- 批准号:
10836880 - 财政年份:2023
- 资助金额:
$ 37.64万 - 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
- 批准号:
10734324 - 财政年份:2023
- 资助金额:
$ 37.64万 - 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
- 批准号:
10740465 - 财政年份:2023
- 资助金额:
$ 37.64万 - 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
- 批准号:
23K04971 - 财政年份:2023
- 资助金额:
$ 37.64万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
- 批准号:
2885451 - 财政年份:2023
- 资助金额:
$ 37.64万 - 项目类别:
Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
- 批准号:
10385926 - 财政年份:2022
- 资助金额:
$ 37.64万 - 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
- 批准号:
10509043 - 财政年份:2022
- 资助金额:
$ 37.64万 - 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
- 批准号:
10704008 - 财政年份:2022
- 资助金额:
$ 37.64万 - 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
- 批准号:
10818273 - 财政年份:2022
- 资助金额:
$ 37.64万 - 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
- 批准号:
10349397 - 财政年份:2022
- 资助金额:
$ 37.64万 - 项目类别: